Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors

AIDS. 2003 Jan 3;17(1):23-32. doi: 10.1097/00002030-200301030-00005.

Abstract

Objective: To test agent and cell-type specificity in insulin resistance induced by prolonged exposure to HIV protease inhibitors (HPI), and to assess its relation to the direct, short-term inhibition of insulin-stimulated glucose uptake.

Methods: Following prolonged (18 h) and short (5-10 min) exposure to HPI, insulin-stimulated glucose transport, protein kinase B (PKB) phosphorylation, and GLUT4 translocation were evaluated in 3T3-L1 adipocytes, fibroblasts, L6 myotubes, and L6 cells overexpressing a myc tag on the first exofacial loop of GLUT4 or GLUT1.

Results: Prolonged exposure of 3T3-L1 adipocytes to nelfinavir, but not to indinavir or saquinavir, resulted in increased basal lipolysis but decreased insulin-stimulated glucose transport and PKB phosphorylation. In addition, impaired insulin-stimulated glucose uptake and PKB phosphorylation were also observed in the skeletal muscle cell line L6, and in 3T3-L1 fibroblasts. Interestingly, this coincided with increased basal glucose uptake as well as with elevated total-membrane glucose transporter GLUT1 protein content. In contrast to these unique effects of nelfinavir, the mere presence of any of the agents in the 5 min transport assay inhibited insulin-stimulated glucose-uptake activity. This appeared to be caused by direct and specific interaction of the drugs with GLUT4 fully assembled at the plasma membrane, since insulin-stimulated cell-surface exposure of an exofacial myc epitope on GLUT4 was normal.

Conclusions: Independent mechanisms for HPI-induced insulin resistance exist: prolonged exposure to nelfinavir interferes with insulin signaling and alters cellular metabolism of adipocytes and muscle cells, whereas a direct inhibitory effect on insulin-stimulated glucose uptake may occurs through specific interaction of HPI with GLUT4.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipocytes / drug effects
  • Adipocytes / metabolism
  • Cell Line
  • Deoxyglucose / metabolism
  • Drug Administration Schedule
  • Fibroblasts / drug effects
  • Fibroblasts / metabolism
  • Glucose Transporter Type 1
  • HIV Protease Inhibitors / pharmacology*
  • Humans
  • Indinavir / pharmacology
  • Insulin Resistance*
  • Lipolysis / drug effects
  • Monosaccharide Transport Proteins / metabolism
  • Muscle, Skeletal / drug effects
  • Muscle, Skeletal / metabolism
  • Nelfinavir / pharmacology
  • Phosphorylation
  • Protein Serine-Threonine Kinases*
  • Proto-Oncogene Proteins / metabolism
  • Proto-Oncogene Proteins c-akt
  • Saquinavir / pharmacology

Substances

  • Glucose Transporter Type 1
  • HIV Protease Inhibitors
  • Monosaccharide Transport Proteins
  • Proto-Oncogene Proteins
  • SLC2A1 protein, human
  • Indinavir
  • Deoxyglucose
  • Protein Serine-Threonine Kinases
  • Proto-Oncogene Proteins c-akt
  • Nelfinavir
  • Saquinavir